Moleculin Biotech, Inc. Profile Avatar - Palmy Investing

Moleculin Biotech, Inc.

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment …

Biotechnology
US, Houston [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of MBRX's Analysis
CIK: 1659617 CUSIP: 60855D200 ISIN: US60855D2009 LEI: - UEI: -
Secondary Listings
MBRX has no secondary listings inside our databases.